66th ASH Annual Meeting: Translational and Post-translational Mechanisms

Symposia: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies Scientific Workshops

Room 33 (San Diego Convention Center)

Moderator:

and Daniel Starczynowski, PhD, University of Cincinnati College of Medicine

Disclosures:

Starczynowski: Curis: Honoraria; Kurome: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Kymera: Consultancy; Tolero: Research Funding; Treeline Biosciences: Research Funding.

This session will focus on translational efficacy and post-translational modifications and their impact in oncogenesis and resistance to therapy.

Moderator Introduction

Daniel Starczynowski, PhD

University of Cincinnati College of Medicine, Cincinnati, OH

Targeting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Acute Myeloid Leukemia

Kira Gritsman, MD, PhD

Albert Einstein College of Medicine, Bronx, NY

Aberrant DUSP6-RSK1 Signaling Axis Mediates Treatment Resistance and Disease Progression in Myeloproliferative Neoplasms

Stephen Oh, MD, PhD

Washington University School of Medicine, Saint Louis, MO

Non-Genetic Adaptation to Bruton Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukemia

Marek Mraz, MD

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic; Department of Internal Medicine—Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Panel Discussion

See more of: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
See more of: Scientific Workshops

<< Previous Session | Next Session >>